| SELEX methods on the road to protein targeting with nucleic acid aptamers P Bayat, R Nosrati, M Alibolandi, H Rafatpanah, K Abnous, M Khedri, ... Biochimie 154, 132-155, 2018 | 237 | 2018 |
| Therapeutic applications of AS1411 aptamer, an update review R Yazdian-Robati, P Bayat, F Oroojalian, M Zargari, M Ramezani, ... International journal of biological macromolecules 155, 1420-1431, 2020 | 216 | 2020 |
| Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: a systematic review of preclinical evidence P Bayat, M Farshchi, M Yousefian, M Mahmoudi, R Yazdian-Robati International Immunopharmacology 95, 107562, 2021 | 51 | 2021 |
| In vitro selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells P Bayat, SM Taghdisi, H Rafatpanah, K Abnous, M Ramezani Talanta 194, 399-405, 2019 | 27 | 2019 |
| Smart delivery of epirubicin to cancer cells using aptamer-modified ferritin nanoparticles R Yazdian-Robati, P Bayat, S Dehestani, M Hashemi, SM Taghdisi, ... Journal of Drug Targeting 30 (5), 567-576, 2022 | 17 | 2022 |
| Aptamer AS1411-functionalized gold nanoparticle-melittin complex for targeting MCF-7 breast cancer cell line P Bayat, K Abnous, S Balarastaghi, SM Taghdisi, M Saeedi, ... Nanomed. J 9 (2), 164-169, 2022 | 9 | 2022 |
| Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells F Nejatollahi, P Bayat, B Moazen F1000Research 6, 156, 2017 | 8 | 2017 |
| Relevance of aptamers as targeting ligands for anticancer therapies P Bayat, A Gholoobi, K Abnous, SM Taghdisi, P Asadi, R Yazdian-Robati Aptamers Engineered Nanocarriers for Cancer Therapy, 85-102, 2023 | | 2023 |
